Urology assessment tools including IPSS for BPH symptoms, PSA density, prostate volume, IIEF-5/SHIM for erectile function, STONE Score for kidney stones, post-void residual assessment, PSA doubling time, CAPRA Score, and bladder volume estimation.
This category currently includes 12 tools, including IPSS Score, PSA Density, and Prostate Volume.
These resources are built for clinicians, trainees, and medically informed patients who need fast bedside calculations. Use the results as decision support and pair them with full clinical context and local guidelines.
Calculate the International Prostate Symptom Score (IPSS/AUA-SI) to assess BPH symptom severity. Mild (0–7): watchful waiting. Moderate (8–19): medications. Severe (20–35): surgical evaluation.
Calculate PSA density (PSAD) to differentiate BPH from prostate cancer. PSAD ≥0.15 ng/mL/mL indicates higher cancer risk and may warrant biopsy even with borderline total PSA levels.
Estimate prostate volume from TRUS or MRI measurements using the ellipsoid formula (π/6 × L × W × H). Normal prostate is 20–30 mL; volume >40 mL suggests clinically significant BPH.
Calculate the IIEF-5 to classify erectile dysfunction severity: Severe (5–7), Moderate (8–11), Mild-Moderate (12–16), Mild (17–21), No ED (22–25). Guides PDE5 inhibitor and referral decisions.
Calculate the STONE score to predict kidney stones in ED patients with flank pain. High score ≥10: 88.6% probability. Moderate 5–9: 51.3%. Low ≤4: 9.2%. Guides CT imaging decisions.
Interpret post-void residual (PVR) volume for urinary retention and BPH evaluation. PVR <50 mL: normal. 50–200 mL: equivocal. >300 mL: significant retention requiring intervention.
Calculate PSA doubling time (PSADT) to monitor prostate cancer progression after treatment. PSADT <3 months: aggressive recurrence. 3–12 months: intermediate. >12 months: lower-risk.
Calculate the UCSF-CAPRA score for prostate cancer risk stratification. Low (0–2), Intermediate (3–5), High (6–10) risk categories guide treatment choice and predict biochemical recurrence.
Calculate the Overactive Bladder Symptom Score (OABSS) to assess OAB severity. Mild (3–5), Moderate (6–11), Severe (≥12) guides anticholinergic or beta-3 agonist therapy selection.
Estimate bladder volume from ultrasound length, width, and height measurements using the ellipsoid formula (0.523 × L × W × H). Essential for urinary retention diagnosis and BPH assessment.
Estimate kidney stone recurrence risk at 2 and 5 years using the ROKS nomogram. Considers stone composition, number of episodes, and risk factors. Guides preventive treatment intensity.
Calculate EORTC risk scores for non-muscle invasive bladder cancer recurrence and progression. Low, Intermediate, or High risk guides BCG therapy, intravesical chemotherapy, and cystoscopy frequency.